Tests RO7568282 against a placebo in early Alzheimer's disease
Compares RO7568282 with a placebo in people in early Alzheimer's disease.
Plain-language title generated from the registry record
Registry title: Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
Key facts
- Where
- Gent, Jette, Kortrijk, Leuven, and Sint-Lambrechts-Woluwe, BelgiumSee the 5 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT07781657, who can take part
Where in Belgium
- Universitair Ziekenhuis GentGent, BelgiumNot yet recruiting
- UZ BrusselJette, BelgiumNot yet recruiting
- Algemeen Ziekenhuis GroeningeKortrijk, BelgiumNot yet recruiting
- UZ LeuvenLeuven, BelgiumNot yet recruiting
- Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hoffmann-La Roche
- Trial code
- NCT07781657EU 2026-526158-14-00
- Record updated
- 6 November 2026
- Original description
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).Read full original descriptionShow less
A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early Symptomatic Alzheimer's Disease
This study aims to compare the effects of RO7568282 versus a placebo in people in the early stages of Alzheimer's disease (AD).
Inclusion: Evidence of AD pathological process, as confirmed by either amyloid positron emission tomography (PET) scan or cerebrospinal fluid (CSF); Mild cognitive impairment (MCI) or mild dementia due to AD; Able to swallow whole capsules; Body mass index (BMI) within the range of 18-34 kilograms per square metre (kg/m²) (at screening); Availability of an appropriate study partner.
Exclusion: Any evidence of a condition other than AD that may affect cognition; Participants must not have unstable or clinically significant cardiovascular disease within the last year, chronic uncontrolled hypertension, or clinically significant electrocardiogram (ECG) abnormalities; History or presence of clinically significant cerebrovascular disease; Clinically significant cerebral abnormalities on magnetic resonance imaging (MRI); Note: Other protocol-defined inclusion/exclusion criteria may apply.